References
- N. ElKassar and R.E. Gress, An overview of IL-7 biology and its use in immunotherapy, J. Immunotoxicol. 7 (2010), pp. 1–7. doi:https://doi.org/10.3109/15476910903453296.
- J. Lorenzo, Chapter 9 - The effects of immune cell products (cytokines and hematopoietic cell growth factors) on bone cells, in Osteoimmunology, 2nd, J. Lorenzo, M.C. Horowitz, Y. Choi, H. Takayanagi, and G. Schett, eds., Academic Press, Cambridge, 2016, pp. 143–167.
- H. Spits, In interleukin-7, in Encyclopedia of Hormones, H.L. Henry and A.W. Norman, eds., Academic Press, Cambridge, 2003, pp. 439–446.
- N. Bosco, F. Agenès, and R. Ceredig, Effects of increasing IL-7 availability on lymphocytes during and after lymphopenia-induced proliferation, J. Immunol. 175 (2005), pp. 162–170. doi:https://doi.org/10.4049/jimmunol.175.1.162.
- J. Lin, Z. Zhu, H. Xiao, M.R. Wakefield, V.A. Ding, Q. Bai, and Y. Fang, The role of IL-7 in immunity and cancer, Anticancer Res. 37 (2017), pp. 963–967.
- R. Mazzucchelli and S.K. Durum, Interleukin-7 receptor expression: Intelligent design, Nat. Rev. Immunol. 7 (2007), pp. 144–154. doi:https://doi.org/10.1038/nri2023.
- A. Sheikh and N. Abraham, Interleukin-7 receptor alpha in innate lymphoid cells: More than a marker, Front. Immunol. 10 (2019), pp. a2897. doi:https://doi.org/10.3389/fimmu.2019.02897.
- B.R. Lawson, R. Gonzalez-Quintial, T. Eleftheriadis, M.A. Farrar, S.D. Miller, K. Sauer, D.B. McGavern, D.H. Kono, R. Baccala, and A.N. Theofilopoulos, Interleukin-7 is required for CD4+ T cell activation and autoimmune neuroinflammation, Clin. Immunol. 161 (2015), pp. 260–269. doi:https://doi.org/10.1016/j.clim.2015.08.007.
- S.L. Silva, A.S. Albuquerque, P. Matoso, B. Charmeteau-de-muylder, R. Cheynier, D. Ligeiro, M. Abecasis, R. Anjos, J.T. Barata, and R.M. Victorino, IL-7-induced proliferation of human naive CD4 T-cells relies on continued thymic activity, Front. Immunol. 8 (2017), pp. a20. doi:https://doi.org/10.3389/fimmu.2017.00020.
- A. Chahroudi and G. Silvestri, Interleukin-7 in HIV pathogenesis and therapy, Eur. Cytokine Netw. 21 (2010), pp. 202–207.
- Y. Levy, C. Lacabaratz, L. Weiss, J.-P. Viard, C. Goujard, J.-D. Lelièvre, F. Boué, J.-M. Molina, C. Rouzioux, and V. Avettand-Fénoêl, Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment, J. Clin. Invest. 119 (2009), pp. 997–1007.
- C. Sportès and R.E. Gress, Interleukin-7 immunotherapy, in Immune-Mediated Diseases. Advances in Experimental Medicine and Biology, M.R. Shurin and Y.S. Smolkin, eds., Springer, New York, 2007, pp. 321–333.
- A. Bikker, C.E. Hack, F.P.J.G. Lafeber, and J.A.G. van Roon, Interleukin-7: A key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction, Curr. Pharm. Res. 18 (2012), pp. 1–10. doi:https://doi.org/10.2174/138161212800165979.
- M. Yasunaga, S. Manabe, and Y. Matsumura, Immunoregulation by IL-7R-targeting antibody-drug conjugates: Overcoming steroid-resistance in cancer and autoimmune disease, Sci. Rep. 7 (2017), pp. 1–14. doi:https://doi.org/10.1038/s41598-017-11255-4.
- J. Gao, L. Zhao, Y.Y. Wan, and B. Zhu, Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy, Int. J. Mol. Sci. 16 (2015), pp. 10267–10280. doi:https://doi.org/10.3390/ijms160510267.
- C.-H. Yuan, X.-Q. Yang, C.-L. Zhu, S.-P. Liu, B.-C. Wang, and F.-B. Wang, Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model, Asian Pac. J. Cancer Prev. 15 (2014), pp. 265–271. doi:https://doi.org/10.7314/APJCP.2014.15.1.265.
- S.A. Rosenberg, C. Sportès, M. Ahmadzadeh, T.J. Fry, L.T. Ngo, S.L. Schwarz, M. Stetler-Stevenson, K.E. Morton, S.A. Mavroukakis, and M. Morre, IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells, J. Immunother. 29 (2006), pp. 313–319. doi:https://doi.org/10.1097/01.cji.0000210386.55951.c2.
- W. Dummer, A.G. Niethammer, R. Baccala, B.R. Lawson, N. Wagner, R.A. Reisfeld, and A.N. Theofilopoulos, T cell homeostatic proliferation elicits effective antitumor autoimmunity, J. Clin. Invest. 110 (2002), pp. 185–192. doi:https://doi.org/10.1172/JCI0215175.
- J.E. Bower, P.A. Ganz, N. Aziz, J.L. Fahey, and S.W. Cole, T-cell homeostasis in breast cancer survivors with persistent fatigue, J. Natl. Cancer Inst. 95 (2003), pp. 1165–1168. doi:https://doi.org/10.1093/jnci/djg0019.
- I. Marković and S.N. Savvides, Modulation of signaling mediated by TSLP and IL-7 in inflammation, autoimmune diseases, and cancer, Front. Immunol. 11 (2020), pp. a1557. doi:https://doi.org/10.3389/fimmu.2020.01557.
- Y. Song, Y. Liu, R. Hu, M. Su, D. Rood, and L. Lai, In vivo antitumor activity of a recombinant IL7/IL15 hybrid cytokine in mice, Mol. Cancer Ther. 15 (2016), pp. 2413–2421. doi:https://doi.org/10.1158/1535-7163.MCT-16-0111.
- L. Belarif, C. Mary, L. Jacquemont, H. Le Mai, R. Danger, J. Hervouet, D. Minault, V. Thepenier, V. Nerrière-Daguin, and E. Nguyen, IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates, Nat. Commun. 9 (2018), pp. 1–13. doi:https://doi.org/10.1038/s41467-018-06804-y.
- C.A. McElroy, J.A. Dohm, and S.T. Walsh, Structural and biophysical studies of the human IL-7/IL-7Rα complex, Structure 17 (2009), pp. 54–65. doi:https://doi.org/10.1016/j.str.2008.10.019.
- OpenEye Scientific Software, Santa Fe, NM, USA, 2018.
- BIOVIA, Dassault systèmes, Pipeline Pilot, San Diego, CA, USA, 2020.
- BIOVIA, Dassault systèmes, Discovery Studio, San Diego, CA, USA, 2020.
- C. Klein, I. Waldhauer, V.G. Nicolini, A. Freimoser-Grundschober, R. Nayak, D.J. Vugts, C. Dunn, M. Bolijn, J. Benz, and M. Stihle, Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines, Oncoimmunology 6 (2017), pp. e1277306. doi:https://doi.org/10.1080/2162402X.2016.1277306.
- Desmond Molecular Dynamics System, D. E. shaw research, New York, NY, USA, 2020. Maestro Desmond Interoperability Tools, Schrödinger, New York, NY, USA, 2020.
- SpectraMax M5e, Molecular devices, San Jose, CA, USA, 2010.
- OriginLab Corporation, Northampton, MA, USA, 2016.
- J. Baell and M.A. Walters, Chemistry: Chemical con artists foil drug discovery, Nature 513 (2014), pp. 481–483. doi:https://doi.org/10.1038/513481a.
- J. Mortier, C. Rakers, M. Bermudez, M.S. Murgueitio, S. Riniker, and G. Wolber, The impact of molecular dynamics on drug design: Applications for the characterization of ligand–macromolecule complexes, Drug Discov. Today 20 (2015), pp. 686–702. doi:https://doi.org/10.1016/j.drudis.2015.01.003.